These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26106188)

  • 1. Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism.
    Xiao C; Dash S; Morgantini C; Adeli K; Lewis GF
    Diabetes; 2015 Jul; 64(7):2310-8. PubMed ID: 26106188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and emerging regulators of intestinal lipoprotein secretion.
    Xiao C; Dash S; Morgantini C; Lewis GF
    Atherosclerosis; 2014 Apr; 233(2):608-615. PubMed ID: 24534456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal lipoprotein overproduction in insulin-resistant states.
    Adeli K; Lewis GF
    Curr Opin Lipidol; 2008 Jun; 19(3):221-8. PubMed ID: 18460911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis.
    Farr S; Baker C; Naples M; Taher J; Iqbal J; Hussain M; Adeli K
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1092-100. PubMed ID: 25675997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.
    Farr S; Adeli K
    Curr Opin Lipidol; 2012 Feb; 23(1):56-61. PubMed ID: 22123671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into incretin-based therapies for treatment of diabetic dyslipidemia.
    Stemmer K; Finan B; DiMarchi RD; Tschöp MH; Müller TD
    Adv Drug Deliv Rev; 2020; 159():34-53. PubMed ID: 32485206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
    Wick A; Newlin K
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptides 1 and 2 in health and disease: a review.
    Marathe CS; Rayner CK; Jones KL; Horowitz M
    Peptides; 2013 Jun; 44():75-86. PubMed ID: 23523778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states.
    Hein GJ; Baker C; Hsieh J; Farr S; Adeli K
    Diabetes; 2013 Feb; 62(2):373-81. PubMed ID: 23028139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes.
    Simsek S; de Galan BE
    Curr Opin Lipidol; 2012 Dec; 23(6):540-7. PubMed ID: 23160401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal lipid absorption and transport in type 2 diabetes.
    Vergès B
    Diabetologia; 2022 Oct; 65(10):1587-1600. PubMed ID: 35908083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretins and Lipid Metabolism.
    Tsimihodimos V; Elisaf M
    Curr Med Chem; 2018; 25(18):2133-2139. PubMed ID: 28413961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.